BeiGene Terminates Allogeneic NK Cell Therapy Collaboration with Shoreline Biosciences

On June 9, 2021, BeOne Medicines and Shoreline Biosciences announced a global exclusive strategic partnership. Linking Shoreline’s iPSC NK cell technology with BeOne Medicines’ preclinical R&D and clinical development capabilities, the collaboration aims to develop and commercialize a portfolio of NK cell therapy-based products for the treatment of various malignant tumors. Under the terms of the agreement, Shoreline will receive a $45 million upfront cash payment from BeOne Medicines and is eligible to receive R&D funding, milestone payments, and royalties upon achieving specific R&D, regulatory, and commercial milestones. Both parties have reached a consensus on this multi-target collaboration, agreeing to jointly develop cell therapies for four therapeutic targets, with the option to expand the partnership in the future. Under the collaboration framework, BeOne Medicines will lead global clinical development, while Shoreline will be responsible for clinical production. BeOne Medicines will hold global commercialization rights, while Shoreline retains the right to commercialize two of the targets in the United States and Canada. Alongside this agreement, BeOne Medicines has the right to acquire a portion of Shoreline's equity in its next round of financing, subject to specific conditions.

It is reported that,According to the terms of the agreement，Shoreline Biosciences, Inc. had received a prepayment of 45 million US dollars in January 2022. 

Statement: Content source "WeChat Official Account: Cell and Gene Therapy Field", BeOne Medicines' official website, etc. The content of this article aims at knowledge sharing; all content is for reference only and does not constitute any advice.